首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >DDIAS promotes invasion and proliferation of non-small cell lung cancer and predicts poor survival of lung cancer patients
【2h】

DDIAS promotes invasion and proliferation of non-small cell lung cancer and predicts poor survival of lung cancer patients

机译:DDIAS促进非小细胞肺癌的侵袭和增殖并预测肺癌患者的不良生存

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

DNA damage-induced apoptosis suppressor (DDIAS), also called hNoxin or C11 or f82, is an anti-apoptotic protein in response to stress. The clinicopathological significance of DDIAS in non-small cell lung cancer patients is largely unknown until now. The purpose of our study is to analyze the clinicopathological association of DDIAS in NSCLC patients. We found that the positive ratio of DDIAS was significantly higher than that in the corresponding non-cancerous lung tissues ( <0.001). Positive DDIAS expression correlated with larger tumor size and positive regional lymph node metastasis ( =0.048 and =0.018, respectively). Online Kaplan-Meier Plotter tool analysis results and survival analysis results of our cohort revealed that both DDIAS gene level ( =0.0048) and protein level ( <0.001) were associated with adverse outcome in NSCLC patients for overall survival, as well as in multiple subgroups divided by different clinicopathological features. Subsequent univariate and multivariate analysis suggested that only positive DDIAS was an independent prognostic factor for overall survival ( =0.018). In NSCLC cell lines, overexpression of DDIAS enhanced the ability of invasion and proliferation, whereas depleting DDIAS depressed the ability of invasion and proliferation. In conclusion, our results suggest that positive DDIAS expression may be a potent prognostic factor in NSCLC patients. DDIAS promotes proliferation and invasion in NSCLC cells and correlates with progression of NSCLC patients.
机译:DNA损伤诱导的细胞凋亡抑制剂(DDIAS),也称为hNoxin或C11或f82,是一种抗应激的抗凋亡蛋白。迄今为止,DDIAS在非小细胞肺癌患者中的临床病理学意义尚不清楚。我们研究的目的是分析NSCLC患者中DDIAS的临床病理关联。我们发现,DDIAS的阳性率显着高于相应的非癌性肺组织(<0.001)。 DDIAS阳性表达与更大的肿瘤大小和局部淋巴结转移阳性相关(分别为= 0.048和= 0.018)。我们队列的在线Kaplan-Meier绘图仪工具分析结果和生存分析结果表明,DDIAS基因水平(= 0.0048)和蛋白质水平(<0.001)与NSCLC患者的总体生存以及多个亚组的不良结局相关按不同的临床病理特征划分。随后的单因素和多因素分析表明,只有阳性的DDIAS是整体生存的独立预后因素(= 0.018)。在NSCLC细胞系中,DDIAS的过表达增强了侵袭和增殖的能力,而耗尽DDIAS则抑制了侵袭和增殖的能力。总之,我们的结果表明DDIAS阳性表达可能是NSCLC患者的有效预后因素。 DDIAS促进NSCLC细胞的增殖和侵袭,并与NSCLC患者的进展相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号